40 results about "Protective antigen" patented technology

The invention discloses a novel microecological preparation composition for preventing and treating feline plague and application of the novel microecological preparation composition, and belongs to the technical field of microecological preparations. The recombinant lactobacillus plantarum NC8-VP2 constructed by a genetic engineering means can efficiently express the feline plague VP2 protein, and finally, a protective antigen expressed by the recombinant lactobacillus plantarum efficiently stimulates an organism to generate a specific antibody, so that the feline plague is prevented, and the use of chemical drugs is reduced. Recombinant escherichia coli BL21-pET32a-MLT constructed by the research can secrete and express melittin (MLT), large-scale production of melittin is realized, melittin and recombinant lactobacillus plantarum NC8-VP2 are further taken as active ingredients, a novel microecological preparation composition for preventing and controlling feline plague is developed and prepared, the morbidity of feline plague can be reduced, clinical symptoms of sick animals can be improved, and the novel microecological preparation composition has a good application prospect. Therefore, the compound has a relatively good application prospect in the aspect of preventing and treating feline plague.

The invention relates to the technical field of veterinary biological products, and particularly provides a porcine epidemic diarrhea virus S protein and related products. The amino acid sequence of the porcine epidemic diarrhea virus S protein fragment is as shown in SEQ ID NO.4. The trimer S protein is constructed by fusing a trimer tag at the C terminal of a protective antigen in a truncated form of the porcine epidemic diarrhea virus S protein. After expression and purification, immunogenicity is judged through animal evaluation, and it is verified that the vaccine prepared from the trimer S protein has the advantages of being high in safety, good in immunogenicity, stable in batches, capable of inducing piglets to generate good immunoreaction and the like, and porcine epidemic diarrhea can be effectively treated or prevented.

The invention provides a triple inactivated vaccine for porcine circovirus type 2, porcine mycoplasmal pneumonia and porcine reproductive and respiratory syndrome as well as a preparation method and application of the triple inactivated vaccine, and belongs to the technical field of biology. The triple inactivated vaccine is prepared on the basis of a porcine circovirus type 2 protective antigen Cap protein, a mycoplasma hyopneumoniae protective antigen recombinant fusion protein F-P46-P65 and a porcine reproductive and respiratory syndrome virus PRRSV-NADC30-like LF strain. According to the triple inactivated vaccine, three major diseases caused by the porcine circovirus type 2, the mycoplasma hyopneumoniae and the porcine reproductive and respiratory syndrome virus can be prevented at the same time through one-time inoculation, the immunization procedure is greatly simplified, the stress reaction caused by multiple immunization to pigs is effectively reduced, and the healthy growth of the pigs is guaranteed. The immune cost of a farm is remarkably reduced, the effect of'immune burden reduction 'is really achieved, and the efficiency and economic benefits of breeding management are improved.

The application discloses a kind of fowl secretory bacterium surface proteins and its screening method and application, belong to biotechnology field.The application can be soluble high-efficiency expression in escherichia coli by screening protective antigen from fowl secretory bacterium heparin binding protein, combined with antigen prediction, soluble analysis and structure-oriented protein design, successfully obtained protein A0A3Q9GGY1, A0A3S9QKJ0 and six-site mutant PLO that can be soluble high-efficiency expression in escherichia coli, has good immunoprotective efficiency, and has accumulated experience for the screening and design of high-yield antigen, and has laid a foundation for the research and development of fowl secretory bacterium vaccine.

There is an urgent need for an effective therapeutic vaccine against tuberculosis (TB), which remains a major public health problem. Current "classical" strategies under development have failed or are suboptimal, and more effective vaccines are needed to achieve the World Health Organization's 2035 End TB Strategy. We have generated a post-exposure / therapeutic TB vaccine candidate (CD40.TB) whose heavy chain consists of an antibody directed against a surface antigen (i.e., CD40) of antigen-presenting cells (i.e., dendritic cells) conjugated to three relevant Mycobacterium tuberculosis (Mtb) antigens and which is liable to induce potent anti-TB humoral and cellular immunity.

The invention discloses arcanobacterium pyogenes surface protein as well as a screening method and application thereof, and belongs to the technical field of biology. According to the invention, a protective antigen which can be soluble and efficiently expressed in escherichia coli is screened from arcanobacterium pyogenes heparin binding protein, and antigen prediction, solubility analysis and structure-oriented protein design are combined; proteins A0A3Q9GGY1, A0A3S9QKJ0 and a six-site mutant PLO which can be soluble and efficiently expressed in escherichia coli and have good immune protection efficacy are successfully obtained, experience is accumulated for screening and design of high-yield antigens, and a foundation is laid for research and development of arcanobacterium pyogenes vaccines.

The application relates to a protective antigen of streptococcus suis disease and application thereof, and belongs to the technical field of biological vaccines. The amino acid sequence shown in SEQ ID No. 1 provided in the application is used as a protective antigen of streptococcus suis disease. The protective antigen is obtained by codon optimization of the nucleotide sequence shown in SEQ ID No. 2, construction of an expression vector and prokaryotic expression, and the protective antigen is verified to be capable of providing good immune cross-protection for type 2 and type 7 streptococcus suis infection in different ways. The application scheme has important significance for research on a general vaccine candidate antigen of multiple serotypes of streptococcus suis and scientific prevention and control of the disease.

A hypothetical protein gene of Echinococcus granulosus and its encoded protein application belong to the field of immunology technology. To address the current stagnation in the development of vaccines for canine anti-Echinococcus granulosus infection and the lagging screening of protective antigens, the present invention first constructs a cDNA expression library of three-day-old Echinococcus granulosus larvae. The library is then immunologically screened using positive serum from dogs infected with Echinococcus granulosus. Through second-generation sequencing and data analysis, an antigenic protein of three-day-old Echinococcus granulosus larvae is screened from the library. The amino acid sequence of the antigenic protein is shown in SEQ ID NO.2, and the nucleotide sequence of the encoding gene is shown in SEQ ID NO.1. It has been verified that the antigenic protein can specifically react with positive serum from dogs infected with Echinococcus granulosus, and has high application value in the development of canine anti-Echinococcus granulosus vaccines and diagnostic reagents.

The application discloses a broad-spectrum protective antigen of avian pathogenic bacterium and application thereof, and belongs to the field of poultry infectious disease prevention and control. The application provides application of avian pathogenic bacterium protein p1 in preparation of a broad-spectrum protective antigen protein of avian pathogenic bacterium, and the amino acid sequence of the avian pathogenic bacterium protein p1 is shown as SEQ ID No. 1. The protective antigen protein has strong immunogenicity and reactivity, and a subunit vaccine prepared by using the antigen protein can provide 90% protection rate of chickens to A, B and C three serotypes of avian pathogenic bacterium, and can effectively prevent infection of the avian pathogenic bacterium.

The present application relates to a kind of mycobacterium tuberculosis protective antigen combination and its application, specifically, the antigen of the application is combination antigen, at least includes the following antigen: Ag85B, Rv2465c, Rv2029c, Rv3406;The application is the vaccine for resisting mycobacterium tuberculosis.

This invention belongs to the field of vaccine technology, specifically relating to a method for effectively activating the body's immune system against tuberculosis infection by identifying candidate antigen epitopes for mRNA vaccines. The method comprises the following steps: screening for population-specific tuberculosis protective antigens based on reverse prediction from a TCR immune repertoire; constructing an mRNA vaccine containing these population-specific tuberculosis protective antigens and identifying the optimal antigen; and evaluating the in vivo immunogenicity, immunogenicity, and immunoprotective effects of the mRNA vaccine. This technical solution combines population-specific common HLA allele profiles with existing tuberculosis-specific TCR databases to target and predict broad-spectrum protective antigens recognized by TCRs shared under the major HLA backgrounds in the population. LNP-mRNA vaccine technology has been established as an ideal platform for delivering these newly discovered advantageous antigens.

The application belongs to the technical field of poultry infectious disease vaccine preparation, and relates to an artificial immunoprotective antigen protein of C type paragallinacean bacillus and application thereof. The artificial immunoprotective antigen protein of C type paragallinacean bacillus provided by the application has an amino acid sequence as shown in SEQ ID No. 1. The antigen protein has strong immunogenicity, and a subunit vaccine prepared by using the antigen protein can obviously enhance the resistance of chickens to C type paragallinacean bacillus, the protection effect of the subunit vaccine is better than that of a whole bacterium inactivated vaccine, and the subunit vaccine can effectively prevent infection of C type paragallinacean bacillus.

A hypothetical protein gene of Echinococcus granulosus and its encoded protein application belong to the field of immunology technology. To address the current stagnation in the development of vaccines for canine anti-Echinococcus granulosus infection and the lagging screening of protective antigens, the present invention first constructs a cDNA expression library of three-day-old Echinococcus granulosus larvae. The library is then immunologically screened using positive serum from dogs infected with Echinococcus granulosus. Through second-generation sequencing and data analysis, an antigenic protein of three-day-old Echinococcus granulosus larvae is screened from the library. The amino acid sequence of the antigenic protein is shown in SEQ ID NO.2, and the nucleotide sequence of the encoding gene is shown in SEQ ID NO.1. It has been verified that the antigenic protein can specifically react with positive serum from dogs infected with Echinococcus granulosus, and has high application value in the development of canine anti-Echinococcus granulosus vaccines and diagnostic reagents.

The invention provides a porcine circovirus type 3 Cap recombinant protein gene, a recombinant rod grain, a protective antigen and a purification method, and belongs to the technical field of biology. The invention utilizes an insect baculovirus eukaryotic expression system to prepare the porcine circovirus type 3 Cap protein protective antigen, and provides a chromatographic purification process of the porcine circovirus type 3 Cap protein protective antigen, which adopts a one-step column chromatography purification method and adopts splitting, filtering and composite affinity chromatography processes to obtain the porcine circovirus type 3 Cap protein protective antigen. According to the method, the porcine circovirus type 3 Cap protein protective antigen is specifically purified from the complex cell lysis solution rapidly and efficiently, the recovery rate in the purification process is high, the purity reaches 90% or above, the treatment capacity is large, the assembly rate of the purified product is high, and the method is simple and suitable for large-scale production.

The invention discloses a CAV-VP1-P2A-VP2 recombinant adenovirus vector live vaccine and application of the CAV-VP1-P2A-VP2 recombinant adenovirus vector live vaccine, and belongs to the technical field of vaccines. According to the characteristics of a natural protective antigen of the chicken anemia virus, fragments beneficial to vaccine preparation are artificially screened, after 305aa-320aa and 78aa-84aa regions with low KU645520.1 protein antigenicity are deleted, a GGGGS connecting arm is used for connection to obtain the VP1-VP2 recombinant protein, and the VP1-VP2 recombinant protein only retains a high-antigenicity core region, can be more efficiently recognized by an immune system, and has a good application prospect. The immune response intensity is enhanced; and the cross-host characteristic of the shuttle plasmid is adapted. The virus titer level of the recombinant adenovirus vector live vaccine obtained on the basis is greater than or equal to 4.74 * 10 < 10 > pfu / mL, and the immune effect on the chicken anemia virus is outstanding.

The invention provides attenuated mutant bacillus anthracis as well as a preparation method and application thereof, and the preparation method comprises the following steps: S1, inserting a first design sequence into a plasmid pMAD to construct a PA gene point mutation plasmid; step S2, constructing a PA mutant Sterne strain by using the Sterne strain and the PA gene point mutation plasmid; and step S3, constructing a pK-Cre vector, and constructing a Stern mPA strain without Erm resistance by using the pK-Cre vector and the PA mutant Stern strain. The prepared vaccine strain is an anthrax vaccine Sterne mPA obtained by genetic engineering modification based on the Sterne vaccine, and an attenuated strain obtained by performing multiple point mutations on a protective antigen (PA), and has the advantages that the capability of generating anthrax toxin and the lethal toxicity effect are lost. And the safety and the effectiveness are obviously improved.

The invention discloses construction and application of a streptococcus suis serotype 2 cps2D gene knockout mutant strain. The cps2D gene knockout mutant strain delta cps2D of the streptococcus suis serotype 2, and a coding gene between the 31st site and the 1000th site of the cps2D gene in the 05ZYH33 strain is replaced by a spectinomycin resistance gene cassette. Capsules of the mutant strain are obviously reduced, the capability of resisting phagocytosis of macrophages is reduced, and animal toxicity test results show that the toxicity of the mutant strain is obviously reduced. The mutant strain provides an important clue for screening of protective antigens of multivalent subunit vaccines, and can be applied to development of S.suis attenuated vaccines and multivalent subunit vaccines.

The present application relates to the technical field of veterinary biological products. Particularly provided are a porcine epidemic diarrhea virus S protein and a related product. The amino acid sequence of a porcine epidemic diarrhea virus S protein fragment is as shown in SEQ ID NO. 4. A trimer tag is fused at the C terminus of a protective antigen in a form of the truncated porcine epidemic diarrhea virus S protein, so as to construct a trimer S protein; and after expression and purification, animal evaluation is performed to determine the immunogenicity. Upon verification, a vaccine prepared from the trimer S protein has the advantages of high safety, good immunogenicity, batch-to-batch consistency, capability of inducing piglets to generate good immune responses, etc., and therefore can effectively treat or prevent porcine epidemic diarrhea.

The present invention relates to a protective antigen combination of Mycobacterium tuberculosis and the use thereof. Specifically, the antigen is a combined antigen and contains at least the following antigens: Ag85B, Rv2465c, Rv2029c and Rv3406. The use is for the preparation of a vaccine against Mycobacterium tuberculosis.

The invention is applicable to the field of gene engineering, and provides a mycobacterium tuberculosis PPE18-LS protein nanoparticle, a preparation method and application thereof, the mycobacterium tuberculosis PPE18-LS protein nanoparticle is formed by sequence fusion of mycobacterium tuberculosis PPE18 protein and LS protein, and the amino acid sequence of the mycobacterium tuberculosis PPE18-LS protein nanoparticle is shown as SEQ ID NO: 2 in a sequence table. According to the invention, the key protective antigen PPE18 of mycobacterium tuberculosis and the LS protein with self-assembly characteristic are subjected to fusion expression, and the PPE18-LS protein nanoparticles with uniform structure are successfully prepared through an Escherichia coli expression system. In-vivo experiment results show that the PPE18-LS protein nanoparticles can effectively activate response pathways of humoral immunity and cellular immunity of a host, show obvious protective efficacy in a mouse model, provide an important technical path for developing a new generation of tuberculosis preventive vaccines, and have wide clinical application prospects and industrialization values.

This invention discloses a fusion protein expressing novel duck reovirus σC protein and duck-derived goose parvovirus VP1 protein, a recombinant duck viral enteritis virus, a vaccine, its construction method, and its applications, belonging to the field of recombinant virus technology. The nucleotide sequence of the fusion protein is shown in positions 300-3568 of SEQ ID NO:1. The fusion protein of this invention can simultaneously express protective antigen proteins of novel duck reovirus (NDRV) and duck-derived goose parvovirus (DGPV). Using CRISPR / Cas9 gene editing technology, the fusion protein is recombined into the US3 gene of duck viral enteritis virus. The resulting recombinant duck viral enteritis virus not only provides protection against virulent duck viral enteritis virus challenge but also provides good protection against NDRV and DGPV, achieving a multi-protection effect with a single injection.

The application discloses a non-toxic genetically engineered toxoid molecule antigen vaccine based on a protective antigen functional domain structure and a preparation method and application thereof. It is determined that botulinum toxin and tetanus toxin both have two key protective antigen molecules, i.e. a receptor binding region Hc and a light chain-transmembrane region L-HN. Based on the important role of the functional domain in immunoprotective efficacy, a non-toxic genetically engineered toxoid or chimeric toxoid multivalent vaccine molecule is designed and prepared by using a biosynthesis technology. The vaccine has two important protective antigens of biological toxins, can produce strong complete protection at a low dose and a small number of immunization times, and can be used as a high-efficiency genetically engineered toxoid vaccine to replace formaldehyde inactivated toxoids for biological toxin prevention. The vaccine has important protective antigens of two different biological toxins, can produce protective efficacy against a plurality of different toxin biological agents, and can be used as a broad-spectrum multivalent vaccine for biological toxin prevention.

The invention discloses an echinococcus granulosus antigen Eg73 as well as a coding gene and application thereof, and belongs to the technical field of immunology. According to the present invention, the Eg73 antigen protein is screened by using the cDNA expression library of the three-day larva of the echinococcus granulosus with high throughput and no prejudice, the preparation method and the application of the antigen protein are further provided, and the purpose of the present invention is to provide the new antigen target for the development of the canine anti-echinococcus granulosus vaccine candidate antigen. The problems that at present, development of vaccines for resisting canine echinococcus granulosus infection lags before, and screening of protective antigens lags are solved, the amino acid sequence of the antigen protein is as shown in SEQ ID NO.1, and the nucleotide sequence for coding the antigen protein is as shown in SEQ ID NO.2. Through verification, the antigen protein can specifically react with positive serum of dogs infected with echinococcus granulosus, and has very high application value in research and development of canine anti-echinococcus granulosus vaccines and diagnostic reagents.

An Echinococcus granulosus antigen Eg73 and its encoding gene and application belong to the field of immunology technology. The present invention utilizes a three-day-old Echinococcus granulosus larvae cDNA expression library to screen the Eg73 antigen protein in a high-throughput, unbiased manner, and further provides a method for preparing the antigen protein and its application, aiming to provide a new antigen target for the development of candidate antigens for canine anti-Echinococcus granulosus vaccines. This solves the current problem of stagnant vaccine development for canine anti-Echinococcus granulosus infection and lagging protective antigen screening. The amino acid sequence of the antigen protein is shown in SEQ ID NO.6, and the nucleotide sequence encoding the antigen protein is shown in SEQ ID NO.7. It has been verified that the antigen protein can specifically react with positive serum from dogs infected with Echinococcus granulosus, and has high application value in the research and development of canine anti-Echinococcus granulosus vaccines and diagnostic reagents.

The present invention refers in general to the field of veterinary medicine and especially to the development of vectored vaccines using the Gallid alphaherpesvirus 3 (GaHV-3) or Marek's disease serotype 2 (MDV-2) vector, which contains protective antigens against different avian pathogens such as Newcastle disease virus (NDV), avian infectious laryngotracheitis virus (ILTV), infectious bursal disease virus (IBDV) or Gumboro disease virus, avian influenza virus (AIV), infectious bronchitis virus (IBV).

This invention discloses a signal peptide, a method, and its application for guiding the secretory expression of exogenous proteins in mycoplasma. The method for guiding the secretory expression of exogenous proteins in mycoplasma includes the step of introducing a signal peptide at one end of the exogenous protein. This invention screens signal peptides with high efficiency in guiding the secretory expression of exogenous proteins and demonstrates that the exogenous proteins are normally expressed and active in mycoplasma. The signal peptide of this invention can be used to guide the secretory expression of mycoplasma and its protective antigens against co-infecting pathogens, and thus for vaccine preparation.

The application discloses a fusion protein PP13138R and application thereof in tuberculosis prevention. Specifically disclosed is a fusion protein comprising HTL, CTL and B cell epitopes in series, PorB, PADRE and RS-09. The application screens 34 epitopes for Mycobacterium tuberculosis, which have good immunogenicity and antigenicity and no toxicity and no sensitization, and have the characteristics of high population coverage and the like. The auxiliary peptide PADRE is further added to improve the immunogenicity of the vaccine, and the PorB and RS-09 are added to endow the vaccine with a targeted delivery function. In-vitro experiments prove that the PP13138R can stimulate human peripheral blood mononuclear cells to produce an immune response, and is an advantage protective antigen. The PP13138R has the advantages of simple preparation method, low cost, high yield and higher safety as a vaccine. The application has great value for the prevention and treatment of active tuberculosis and latent tuberculosis infection.

An Echinococcus granulosus antigen Eg142, its encoding gene, and its application belong to the field of immunology technology. The present invention utilizes the Eg142 antigen protein, obtained through high-throughput, unbiased screening of a three-day-old Echinococcus granulosus larvae cDNA expression library, to develop a new antigen candidate for a canine Echinococcus granulosus vaccine. This solves the current problems of stagnation in the development of canine Echinococcus granulosus vaccines and the lag in screening for protective antigens. The amino acid sequence of the antigen protein is shown in SEQ ID NO.3, and the nucleotide sequence encoding the Eg142 protein is shown in SEQ ID NO.4. It has been verified that the antigen protein can specifically react with positive serum from dogs infected with Echinococcus granulosus, and has high application value in the development of canine Echinococcus granulosus vaccines.

This invention discloses a chimeric antiviral cross-protective antigen mRNA vaccine, its preparation method, and its application. The vaccine consists of lipid materials encapsulating either a first or second type of mRNA, forming nanolipid nanoparticles containing mRNA fragments. The first type of mRNA is obtained through in vitro transcription using a first DNA template, and the second type of mRNA is obtained through in vitro transcription using a second DNA template. The vaccine of this invention possesses the advantage of multi-antigen comprehensive immunity: each vaccine combines one EEV core surface antigen and one IMV core surface antigen. This chimeric strategy can simultaneously induce highly efficient and specific immunity against both types of viral infection particles, both limiting initial viral entry into cells and effectively clearing free viruses from the circulatory system. It not only stimulates strong humoral immunity but also induces specific cellular immune responses, thereby significantly enhancing the vaccine's broad-spectrum cross-protective efficacy against orthopox, vaccinia virus, and other orthopox viruses.